NEW YORK (GenomeWeb News) – The Debiopharm Group said on Thursday it has inked a one-year collaboration deal with Quartz Bio for support of the biopharmaceutical group’s translational projects.

Quartz Bio, a clinical bioinformatics firm spun out by Merck Serono last September, will provide its expertise in computational analyses and biomarker discovery to Debiopharm’s projects, which are anticipated to range from next-generation sequencing and clinical biomarker data analyses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.